8-K: Septerna Reports Fourth Quarter and Full Year 2024 Financial Results, Provides Corporate Update

Septerna, Inc. announces its Q4 and full year 2024 financial results, highlighting preclinical advancements and upcoming milestones, including plans to select a next-generation oral small molecule PTH1R agonist and initiate a Phase 1 trial for SEP-631 in 2025.

Summary

• Septerna, Inc., a biotechnology company focused on GPCR drug discovery, announced its fourth quarter and full year 2024 financial results.
• The company is advancing its pipeline of oral small molecule programs using its Native Complex Platform.
• A Phase 1 clinical trial of SEP-786 was discontinued in February 2025 due to elevated bilirubin levels observed in the multiple ascending dose (MAD) portion of the trial.
• Septerna plans to select a next-generation oral small molecule PTH1R agonist development candidate by the end of 2025.
• The company anticipates initiating a Phase 1 clinical trial for SEP-631, a selective MRGPRX2 NAM for mast cell diseases, in 2025.
• Septerna is progressing its TSHR NAM program for Graves disease and thyroid eye disease, as well as its incretin receptor agonist programs for metabolic diseases.
• Gil Labrucherie was appointed as chief financial officer in January 2025.
• As of December 31, 2024, Septerna's cash, cash equivalents, and marketable securities totaled $420.8 million.
• The company expects its current cash position to support planned operations into early 2028.
• Research and development (R&D) expenses were $19.3 million for the fourth quarter of 2024 and $65.3 million for the full year ended December 31, 2024.
• General and administrative (G&A) expenses were $5.6 million for the fourth quarter of 2024 and $16.6 million for the full year ended December 31, 2024.
• Net loss totaled $20.7 million for the fourth quarter of 2024 and $71.8 million for the full year ended December 31, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the discontinuation of the SEP-786 program and the reported net loss are negative factors, the company's strong cash position, advancement of other programs, and experienced management team provide a basis for optimism.

Positives

• Septerna has a strong cash position of $420.8 million, expected to fund operations into early 2028.
• The company is advancing multiple promising next-generation PTH1R agonists.
• SEP-631, a selective MRGPRX2 NAM for mast cell diseases, is on track to enter the clinic in 2025.
• Septerna is making good progress with its TSHR program for Graves disease and thyroid eye disease.
• The company is also progressing with its singleand multi-acting incretin receptor agonist programs for metabolic diseases.

Negatives

• The Phase 1 clinical trial of SEP-786 was discontinued due to elevated bilirubin levels.
• The company reported a net loss of $20.7 million for the fourth quarter of 2024 and $71.8 million for the full year ended December 31, 2024.

Risks

• The discontinuation of the SEP-786 program due to elevated bilirubin levels raises concerns about the safety profile of similar compounds.
• The company faces risks associated with clinical development outcomes, including unexpected safety or efficacy findings.
• There are uncertainties related to obtaining regulatory approvals for future clinical development of potential product candidates.
• The company's success depends on its ability to identify and enter into future license agreements and collaborations.

Future Outlook

Septerna plans to select a next-generation oral small molecule PTH1R agonist development candidate by the end of 2025 and initiate a Phase 1 clinical trial for SEP-631 in 2025; the company expects its current cash position to support its planned operations into early 2028.

Management Comments

• Our Native Complex Platform continues to produce a deep pipeline of oral small molecule programs, said Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna.
• Following the recent decision to discontinue our SEP-786 program, we remain focused on the opportunity to transform treatment for patients with hypoparathyroidism and are rapidly advancing multiple promising next-generation PTH1R agonists with the potential to select a next-generation candidate to advance toward the clinic later this year.
• With an experienced team, powerful platform and strong balance sheet, we believe we are well positioned to execute on our mission to develop multiple impactful GPCR medicines.

Industry Context

Septerna's focus on GPCR drug discovery aligns with a broader industry trend of targeting these receptors for therapeutic intervention; GPCRs are involved in a wide range of physiological processes, making them attractive targets for drug development.

Comparison to Industry Standards

• Septerna's cash runway into early 2028 is relatively strong compared to other biotech companies of similar size and stage.
• The discontinuation of SEP-786 due to elevated bilirubin levels is a setback, but the company's focus on next-generation PTH1R agonists demonstrates resilience.
• The planned initiation of a Phase 1 trial for SEP-631 in 2025 is a positive step forward for the company's MRGPRX2 NAM program.
• Companies like Amgen and Radius Health have also been developing PTH1R agonists for hypoparathyroidism, indicating a competitive landscape.
• Septerna's Native Complex Platform is a differentiating factor that could give it an edge in GPCR drug discovery.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the discontinuation of the SEP-786 program and the reported net loss.
• Employees may be affected by the company's strategic shift towards next-generation PTH1R agonists.
• Patients with hypoparathyroidism may benefit from the development of new PTH1R agonists.
• Patients with mast cell diseases may benefit from the development of SEP-631.
• The company's suppliers and creditors may be affected by its financial performance.

Next Steps

• Septerna plans to select a next-generation oral small molecule PTH1R agonist development candidate by the end of 2025.
• The company anticipates initiating a Phase 1 clinical trial for SEP-631 in 2025.
• Septerna will continue to progress its TSHR NAM program and incretin receptor agonist programs.

Key Dates

Keywords

Septerna, GPCR, drug discovery, financial results, clinical trial, PTH1R agonist, SEP-631, MRGPRX2 NAM, TSHR NAM, incretin receptor, metabolic diseases, hypoparathyroidism, mast cell diseases, Graves disease, thyroid eye disease